Balchem's Q3 Earnings Soar 19% on Strong Sales Growth

Ticker: BCPC · Form: 10-Q · Filed: Oct 21, 2025 · CIK: 9326

Balchem CORP 10-Q Filing Summary
FieldDetail
CompanyBalchem CORP (BCPC)
Form Type10-Q
Filed DateOct 21, 2025
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$000
Sentimentbullish

Sentiment: bullish

Topics: Earnings Growth, Revenue Increase, Debt Reduction, Specialty Chemicals, Nutrition, Financial Performance, Stockholder Equity

Related Tickers: BCPC

TL;DR

**Balchem is crushing it, with earnings up 19% and debt down, making it a solid buy for growth-oriented investors.**

AI Summary

Balchem Corporation reported robust financial performance for the three and nine months ended September 30, 2025. Net sales increased by 11.5% to $267.56 million for the three months ended September 30, 2025, up from $239.94 million in the prior year. For the nine months, net sales grew 8.3% to $773.54 million from $713.68 million. Net earnings saw a significant jump, rising 19.1% to $40.29 million for the quarter and 21.8% to $115.62 million for the nine-month period. Diluted EPS increased to $1.24 for the quarter and $3.54 for the nine months, compared to $1.03 and $2.90, respectively, in 2024. The company's cash and cash equivalents increased to $65.09 million as of September 30, 2025, from $49.52 million at December 31, 2024. Total assets grew to $1.66 billion from $1.58 billion, while total liabilities decreased to $363.17 million from $425.46 million, primarily due to a reduction in revolving loan debt from $190.00 million to $154.00 million. Stockholders' equity increased by $147.95 million to $1.30 billion, driven by retained earnings and a substantial foreign currency translation adjustment of $65.58 million.

Why It Matters

Balchem's strong performance, particularly the 19.1% net earnings growth and 11.5% sales increase, signals robust demand for its specialized nutritional and industrial products, which is critical for investors. The reduction in revolving loan debt by $36 million demonstrates effective capital management and strengthens the company's financial position, potentially leading to higher shareholder returns. For employees, continued growth and profitability suggest job security and potential for expansion. In a competitive market, Balchem's ability to consistently grow sales and earnings, coupled with strategic acquisitions and R&D investments, positions it favorably against peers, reinforcing its market leadership in key segments.

Risk Assessment

Risk Level: low — The company's risk level is low due to strong financial performance, including a 19.1% increase in net earnings to $40.29 million for the quarter and a significant reduction in revolving loan debt from $190.00 million to $154.00 million. This debt reduction, coupled with an increase in cash and cash equivalents to $65.09 million, indicates a healthy liquidity position and improved financial stability.

Analyst Insight

Investors should consider increasing their position in BCPC, given the strong earnings growth and effective debt reduction. The company's consistent performance and strategic financial management suggest continued stability and potential for future capital appreciation. Monitor upcoming FASB accounting standard changes for potential disclosure impacts.

Financial Highlights

debt To Equity
0.28
revenue
$267.56M
operating Margin
20.4%
total Assets
$1.66B
total Debt
$166.25M
net Income
$40.29M
eps
$1.24
gross Margin
35.7%
cash Position
$65.09M
revenue Growth
+11.5%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Sales$267.56M+11.5%
Total Net Sales$773.54M+8.3%

Key Numbers

Key Players & Entities

FAQ

What were Balchem Corporation's net sales for the three months ended September 30, 2025?

Balchem Corporation reported net sales of $267,558 thousand for the three months ended September 30, 2025, an increase from $239,940 thousand in the same period of 2024.

How did Balchem's net earnings change for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Balchem's net earnings increased to $115,620 thousand, up from $94,892 thousand in the prior year, representing a 21.8% growth.

What was Balchem Corporation's diluted EPS for the third quarter of 2025?

Balchem Corporation's diluted earnings per common share for the three months ended September 30, 2025, was $1.24, compared to $1.03 for the same period in 2024.

Did Balchem Corporation reduce its debt in the nine months ended September 30, 2025?

Yes, Balchem Corporation significantly reduced its revolving loan balance from $190,000 thousand at December 31, 2024, to $154,000 thousand as of September 30, 2025.

What was the total stockholders' equity for Balchem Corporation as of September 30, 2025?

As of September 30, 2025, Balchem Corporation's total stockholders' equity stood at $1,297,864 thousand, an increase from $1,149,913 thousand at December 31, 2024.

What new accounting standards did Balchem Corporation adopt recently?

Balchem Corporation adopted ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures," on December 31, 2024, and applied it retrospectively to all prior periods presented.

How many shares were available for future awards under Balchem's omnibus incentive plan as of September 30, 2025?

As of September 30, 2025, Balchem's omnibus incentive plan had 680,930 shares available for future awards, indicating capacity for future equity compensation.

What was the impact of foreign currency translation on Balchem's comprehensive income?

For the nine months ended September 30, 2025, Balchem reported a foreign currency translation adjustment of $65,583 thousand, which significantly contributed to other comprehensive income.

What are the performance metrics for Balchem's performance share awards granted in 2025?

For grants made in 2025, Balchem's performance share awards are based on an EBITDA percentage growth hurdle, modified by the Company's Total Shareholder Return (TSR) performance relative to the Russell 2000 index constituents.

What is the current status of Balchem's cash and cash equivalents?

Balchem's cash and cash equivalents increased by $15,578 thousand during the nine months ended September 30, 2025, reaching a total of $65,093 thousand at the end of the period.

Risk Factors

Industry Context

Balchem operates in the specialty ingredients sector, serving diverse end markets including human nutrition and health, animal nutrition and health, and specialty products. The industry is characterized by innovation, demand for sustainable and health-focused solutions, and consolidation. Key trends include the growing demand for plant-based ingredients, personalized nutrition, and advanced animal feed additives.

Regulatory Implications

Balchem faces regulatory scrutiny related to food safety, environmental standards, and chemical handling across its operating segments. Compliance with evolving regulations from bodies like the FDA, EPA, and international equivalents is crucial to avoid penalties, operational disruptions, and maintain market access.

What Investors Should Do

  1. Monitor margin trends
  2. Analyze goodwill and intangibles
  3. Evaluate debt reduction impact
  4. Track foreign currency impact

Key Dates

Glossary

Accumulated other comprehensive income (loss)
Represents unrealized gains and losses that have not been included in net income but affect equity. For Balchem, this includes foreign currency translation adjustments. (A significant positive adjustment of $65.58M in this category for the nine months ended Sept 30, 2025, boosted total stockholders' equity.)
Goodwill
An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. It represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and recognized. (Goodwill represents a substantial portion of Balchem's assets ($816.49M as of Sept 30, 2025), indicating significant past acquisitions.)
Right of use assets - operating leases
Represents the value of a company's right to use an asset for the duration of an operating lease. This is recognized on the balance sheet under ASC 842. (These assets, along with corresponding liabilities, reflect Balchem's commitments for leased properties and equipment.)
Diluted EPS
Earnings per share calculated using the weighted average number of outstanding common shares plus all dilutive potential common shares (such as stock options and convertible securities). (Diluted EPS increased to $1.24 for Q3 2025 from $1.03 in Q3 2024, indicating improved profitability on a per-share basis.)
Revolving loan
A type of credit facility that allows a company to borrow, repay, and re-borrow funds up to a certain limit over a specified period. (Balchem reduced its revolving loan balance from $190.00M to $154.00M, significantly lowering its short-term debt and interest expense.)

Year-Over-Year Comparison

Balchem Corporation demonstrates significant year-over-year improvement. Net sales for the nine months ended September 30, 2025, increased by 8.3% to $773.54 million, with Q3 sales up 11.5% to $267.56 million. Net earnings saw even stronger growth, rising 21.8% year-to-date to $115.62 million and 19.1% in Q3 to $40.29 million. This improved profitability is reflected in diluted EPS, which grew from $2.90 to $3.54 year-to-date and $1.03 to $1.24 for the quarter. The balance sheet has been strengthened, with cash increasing by $15.58 million to $65.09 million and total liabilities decreasing by $62.29 million, primarily due to a $36 million reduction in revolving loan debt, leading to a substantial increase in stockholders' equity by $147.95 million.

Filing Stats: 4,683 words · 19 min read · ~16 pages · Grade level 14.3 · Accepted 2025-10-21 16:18:33

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Earnings for the Three and Nine Months Ended Septemb er 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 5. Other Information 37 Item 6. Exhibits 38 SIGNATURE PAGE 39 Table of Contents

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements BALCHEM CORPORATION Condensed Consolidated Balance Sheets (Dollars in thousands, except share and per share data) Assets September 30, 2025 December 31, 2024 Current assets: (unaudited) Cash and cash equivalents $ 65,093 $ 49,515 Accounts receivable, net of allowance for credit losses of $ 829 and $ 909 at September 30, 2025 and December 31, 2024, respectively 131,542 119,662 Inventories, net 132,435 130,802 Prepaid expenses 8,904 8,054 Other current assets 5,741 5,737 Total current assets 343,715 313,770 Property, plant and equipment, net 297,842 282,154 Goodwill 816,494 780,030 Customer relationships and lists, net 136,129 132,484 Other intangible assets with finite lives, net 31,330 32,566 Right of use assets - operating leases 15,916 15,320 Right of use assets - finance lease 1,573 1,730 Other non-current assets 18,032 17,317 Total assets $ 1,661,031 $ 1,575,371 Liabilities and Stockholders' Equity Current liabilities: Trade accounts payable $ 46,979 $ 54,745 Accrued expenses 48,592 43,750 Accrued compensation and other benefits 20,089 22,886 Dividends payable 113 28,510 Income taxes payable 6,451 4,466 Operating lease liabilities - current 3,943 3,134 Finance lease liabilities - current 202 194 Total current liabilities 126,369 157,685 Revolving loan 154,000 190,000 Deferred income taxes 47,602 43,722 Operating lease liabilities - non-current 12,257 12,967 Finance lease liabilities - non-current 1,596 1,749 Other long-term obligations 21,343 19,335 Total liabilities 363,167 425,458 Commitments and contingencies (Note 15) Stockholders' equity: Preferred stock, $ 25 par value. Authorized 2,000,000 shares; no ne issued and outstanding — — Common stock, $ 0.0667 par value. Authorized 120,000,000 shares; 32,376,314 and 32,527,244 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 2,160 2,170 Additional paid-in capital 140,995 173,997 Retained earnings 1,113

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing